CLEC9A Chimeric Protein Complexes for Targeted IFNα Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing chimeric proteins face challenges in achieving high precision delivery to targets, maintaining tolerability, and ensuring adequate in vivo exposure time while avoiding systemic toxicity and rapid clearance, which limits their therapeutic efficacy.
Innovation Solution
A chimeric protein complex comprising a targeting moiety that binds to Clec9A, a modified human IFNα2, and a modified Fc domain, engineered to enhance precision, stability, and solubility, with reduced receptor interaction until target binding, allowing for regulated effector function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If a chimeric protein is engineered with a modified signaling agent to reduce systemic toxicity, then tolerability is improved, but the signaling agent's effector function is attenuated
Solution Approach 1:
The signaling agent's activity is made dynamic through conditional engagement. The modified signaling agent (e.g., IFNα2 with reduced affinity) is only activated upon binding to the targeting element, transitioning from an inactive/low-activity state in circulation to an active state at the target. This dynamic activation allows the protein to maintain low systemic toxicity while providing reliable effector function when needed.
Solution Approach 2:
The targeting element acts as an intermediary that bridges the modified signaling agent and its receptor. The targeting element binds to the modified signaling agent with high affinity, then presents it to the target cell receptor. This intermediary mechanism allows the signaling agent to maintain reduced baseline activity while ensuring reliable activation only when the targeting element mediates its engagement with the target.
2Ease of manufacture
If the chimeric protein uses a single contiguous polypeptide chain, then manufacturing is simplified, but achieving desired pharmacokinetic properties and tissue penetrance becomes difficult
Solution Approach 1:
The chimeric protein is segmented into distinct functional domains: a targeting element (e.g., VHH antibody fragment), a modified signaling agent (e.g., IFNα2), and optional Fc domains. These segments can be produced separately and then assembled into the final chimeric protein complex, allowing optimization of each component's pharmacokinetic properties while maintaining manufacturing feasibility through modular assembly.
Solution Approach 2:
The chimeric protein is constructed as a composite molecule combining different functional components with complementary properties. The targeting element provides binding specificity, the modified signaling agent provides regulated effector function, and Fc domains (when included) provide extended half-life and enhanced stability. This composite structure achieves superior pharmacokinetic properties that would be difficult to attain in a single polypeptide chain.
3Object-generated harmful factors
If the signaling agent is modified to reduce receptor interaction, then systemic adverse events are reduced, but the ability to engage target receptors is compromised
Solution Approach 1:
The receptor engagement is made dynamic and conditional. The modified signaling agent has reduced baseline affinity for its receptor, but upon binding to the targeting element, it undergoes a conformational or positional change that enables high-affinity engagement with the target cell receptor. This dynamic transition ensures reliable target engagement only when the targeting element is present, preventing spurious receptor interaction and systemic adverse events.
Solution Approach 2:
The targeting element serves as a mediator that enables specific target engagement while preventing non-specific interactions. It binds the modified signaling agent with high affinity, then presents it to the target cell receptor in a manner that facilitates specific receptor engagement. This intermediary mechanism allows the signaling agent to maintain reduced baseline receptor interaction (preventing systemic adverse events) while ensuring reliable target engagement when mediated by the targeting element.
Data Source
AI summary
The present invention relates, in part, to chimeric protein complexes including an anti-ClecSA targeting moiety, modified Fc domain, and a modified human IFNα and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric protein complexes and their use in the treatment of various diseases.